SUN Pharmaceutical Industries Limited Dexamethasone Export Data — India (DGFT 2022–2026)

Name: SUN Pharmaceutical Industries Limited Dexamethasone Export Records India — #3 Exporter, 65 Shipments, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Dexamethasone

India Pharmaceutical Trade Intelligence

$181.4M808 Suppliers176 CountriesHS 30049099

ExportsIndia → UNITED STATES62.7%India → ETHIOPIA8.0%

ImportsBRAZIL → India$30.7B CHINA → India$42.9M

#1 Buyer: DR REDDYS

SUN Pharmaceutical Industries Limited — Dexamethasone Exporter #3 | $3.3M Trade Value | TransData Nexus | TransData Nexus

SUN Pharmaceutical Industries Limited — Dexamethasone Exporter Profile

Indian Pharmaceutical Exporter · #3 for Dexamethasone · $3.3M export value · DGFT Verified

SUN Pharmaceutical Industries Limited is the #3 Indian exporter of Dexamethasone with $3.3M in export value and 65 verified shipments. SUN Pharmaceutical Industries Limited holds a 1.8% market share in Dexamethasone exports across 5 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.

SUN Pharmaceutical Industries Limited — Dexamethasone Export Profile: Buyers & Destinations

SUN Pharmaceutical Industries Limited Dexamethasone export treemap — buyers and destination countries | TransData Nexus

Where Does SUN Pharmaceutical Industries Limited Export Dexamethasone?

Country	Value	Shipments	Share
UNITED STATES	$2.3M	46	71.5%
CANADA	$828.7K	19	26.1%
MEXICO	$50.0K	1	1.6%
RUSSIA	$25.5K	2	0.8%

Who Are the Top Buyers of Dexamethasone from SUN Pharmaceutical Industries Limited?

Buyer	Country	Value	Orders
SUN PHARMACEUTICAL INDUSTRIES,INC.	UNITED STATES	$1.3M	26
SUN PHARMACEUTICAL INDUSTRIES INC	UNITED STATES	$650.0K	13
TARO PHARMACEUTICALS INC.,	CANADA	$402.0K	9
TARO PHARMACEUTICALS INC	CANADA	$300.0K	6
SUN PHARMACEUTICAL INDUSTRIES,INC,	UNITED STATES	$150.0K	3
SUN PHARMACEUTICAL INDUSTRIES INC.	UNITED STATES	$150.0K	3
TARO PHARMACEUTICALS INC.	CANADA	$76.7K	3
SUN PHARMACEUTICAL INDUSTRIES,INC..	UNITED STATES	$50.0K	1
GRADINTER S.C	MEXICO	$50.0K	1
SUN PHARMA CANADA INC	CANADA	$50.0K	1

SUN Pharmaceutical Industries Limited supplies Dexamethasone to 13 buyers globally. The largest buyer is SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES), followed by SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES) and TARO PHARMACEUTICALS INC., (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Dexamethasone Formulations Does SUN Pharmaceutical Industries Limited Export?

Product Description / Formulation	Value	Shipments
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (	$550.0K	11
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP,7.5ML- USA (BATCH NO AS PER INVOICE)	$373.4K	8
CIPROFLOXACIN 0.3% AND DEXAMETHASONE	$250.0K	5
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP (FOR CANADA)	$150.0K	3
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP,7.5ML- USA PACK : 01*01 (BATCH NO AS PER INVO	$150.0K	3
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP, 7.5ML USA (BATCH NO AS PER INVOICE)(55 SHI	$150.0K	3
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP,7.5ML- USA PACK : 01*01	$150.0K	3
CIPROFLOXACIN 0 3 AND DEXAMETHASONE 0 1 STERILE OTIC SUSPENSION USP 7 5ML USA PACK 01 01 BATCH NO AS PER INVO	$150.0K	3
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP, 7.5ML- USA PACK : 01*01 (BATCH NO AS PER INV	$100.0K	2
CIPROFLOXACIN (0.3%) AND DEXAMETHASONE (0.1%) STERILE OTIC SUSPENSION USP, 7.5ML[45699 PACK X 1 BOTTLE] (BATCH NO. BAF0	$100.0K	2

SUN Pharmaceutical Industries Limited exports 35 distinct Dexamethasone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CIPROFLOXACIN (0.3%) AND DEXAMETHASONE ( with 11 shipments worth $550.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does SUN Pharmaceutical Industries Limited Compare to Nearest Dexamethasone Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	MYLAN LABORATORIES LIMITED	$6.1M	135	4	$45.1K
7	SENTISS PHARMA PRIVATE LIMITED	$4.5M	90	6	$50.0K
3	SUN PHARMACEUTICAL INDUSTRIES LIMITED ★	$3.3M	65	5	$50.0K
8	EUGIA PHARMA SPECIALITIES LIMITED	$3.2M	64	1	$50.0K
4	SAKAR HEALTHCARE LIMITED	$2.9M	57	6	$50.0K

SUN Pharmaceutical Industries Limited ranks #3 among 808 Indian Dexamethasone exporters. Average shipment value of $50.0K compared to the market average of $39.8K. The closest competitors by value are MYLAN LABORATORIES LIMITED and SENTISS PHARMA PRIVATE LIMITED.

Which Indian Ports Ship Dexamethasone Exports?

Port	Shipments	% Share
SAHAR AIR	1,214	13.8%
SAHAR AIR CARGO ACC (INBOM4)	1,121	12.8%
NHAVA SHEVA SEA (INNSA1)	748	8.5%
DELHI AIR CARGO ACC (INDEL4)	509	5.8%
DELHI AIR	476	5.4%
JNPT/ NHAVA SHEVA SEA	472	5.4%
Bombay Air	327	3.7%
JNPT	320	3.6%

Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Dexamethasone Exports

Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)

In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)

The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)

SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)

Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Dexamethasone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 70 individual customs records matching SUN Pharmaceutical Industries Limited exporting Dexamethasone, covering 35 formulations to 5 countries via 13 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 176+ countries, 2,257+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Dexamethasone

Dexamethasone

SUN Pharmaceutical Industries Limited — Dexamethasone Exporter Profile

SUN Pharmaceutical Industries Limited — Dexamethasone Export Profile: Buyers & Destinations

Where Does SUN Pharmaceutical Industries Limited Export Dexamethasone?

Who Are the Top Buyers of Dexamethasone from SUN Pharmaceutical Industries Limited?

What Is India's Total Dexamethasone Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?

What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Dexamethasone Exports?

How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Dexamethasone Exporters?

What Dexamethasone Formulations Does SUN Pharmaceutical Industries Limited Export?

Regulatory Requirements: Exporting Dexamethasone to Key Markets

United States — FDA

Canada — HC

Mexico — COFEPRIS

How Does SUN Pharmaceutical Industries Limited Compare to Nearest Dexamethasone Exporters?

Which Indian Ports Ship Dexamethasone Exports?

Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Dexamethasone Exports

SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards

About SUN Pharmaceutical Industries Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Dexamethasone Export Data from SUN Pharmaceutical Industries Limited

Dexamethasone Stats

Company Overview

Top Products by SUN Pharmaceutical Industries Limited

Related Analysis

Need Detailed Export Data?

Data Source